Korea Mulls New Biosimilar Guidelines As Pipeline Surges
This article was originally published in PharmAsia News
As more biosimilar products are set to be released in South Korea, with a hefty number of ongoing late-stage clinical trials, the country is seeking to introduce a new separate guideline for insulin biosimilars. While South Korea has introduced biosimilar guidelines relatively earlier than some others, a local institute suggests these still need to be improved, pointing to a lack of clarity and implementation issues.
You may also be interested in...
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.